Abstract:
Pharmaceutical compositions comprising a therapeutically effective amount of (+) 2-methylpiperidine and a pharmaceutically-acceptable carrier or diluent, as well as to a method of treating cognitive, neurological and mental disorders, which are characterized by decreased cholinergic function in humans and lower mammals, by administration of (+) 2-methylpiperidine, optionally with a nicotinic agonist.
Abstract:
A solution pumping system (10) including a disposable pump cassette (12) is disclosed, with the system configured for efficient and accurate preparation of parental admixture solutions. The system includes a pump driver (14) having a reciprocable pump plunger (36) and a plurality of associated valve actuators (32, 34). The disposable pump cassette of the system is configured for removable positioning in operative association with the pump driver, and includes a positive displacement pump (31) configured for operation by the reciprocable pump plunger (36). The pump cassette further includes a plurality of liquid inlets (24), and at least one liquid outlet (26) joined in fluid communication with the inlets. By selective operation of the valve actuators of the pump driver, one or more selected source solutions are drawn through the pump inlets by the positive displacement pump, and directed through the pump outlet to an admixture solution container.
Abstract:
An isolated DNA segment is disclosed which is derived from a Saccharomyces cerevisiae sorbitol dehydrogenase gene and which functions to increase expression of an associated foreign polypeptide when the DNA segment and the gene coding for the foreign polypeptide are operably linked in a vector in such a manner that the vector is replicated and carried by a host yeast cell. The functionally active portion of the segment is under the control: (i) a transcriptional regulatory sequence of the sorbitol dehydrogenase of Saccharomyces cerevisiae, (ii) a translation initiation regulatory sequence of the sorbitol dehydrogenase gene of Saccharomyces cerivisiae, and (iii) a termination regulatory sequence of the sorbitol dehydrogenase gene of Saccharomyces cerivisiae. Yeast cells containing these regulatory sequences linked to a foreign DNA sequence are grown in medium containing sorbitol under conditions permitting a foreign polypeptide to be expressed.
Abstract:
A closure (10) for sealing the open end of a container and usable with a blunt entry device includes a resilient body having a central diaphragm portion (14), peripheral flange portion (16), and a hollow plug portion (18). The plug portion (18) depends from the circumference juncture of the flange and diaphragm portions and sealingly engages the interior of the open end of the container. The diaphragm portion (14) is configured for minimal entry force by the blunt entry device. A metal ferrule (36) which secures the stopper to the container has an annular skirt portion for engagement with the exterior of the container.
Abstract:
A class of potent LHRH decapeptide antagonists possess N-alkylated aminoacyl residues where the side-chain portion of the residue is a 4-(substituted-amino)phenylalanyl, 4-(substituted-amino)cyclohexylalanyl, or OMEGA -(substituted-amino)alkyl group, and additionally the aminoacyl residues at position 5 are N-alkylated on the nitrogen atom of the peptide backbone.
Abstract:
A process for the removal of phytate from protein using ion exchange has been developed. The process involves the upflow passage of a protein slurry at an elevated temperature through a strong base anion exchanger in the chloride form. The weak base anion sites inherent to the resin have been converted to the free base form. The anion exchange material can easily be regenerated. The process can be used on-line, yields phytate removal of greater than 90 %, has high (greater than 90 %) protein recovery, is cost-effective, and is environmentally friendly.
Abstract:
A system (10) for automatically testing biological fluids includes a network database (26) which holds test protocols and test results for identified samples. The system (10) tracks the samples by their identifier through the system to testing equipment (16) which is also coupled to the network (24). The system (10) records the tests performed and the times they were performed and monitors any reagents used in the test being run. In addition, the system (10) monitors any incubation of the samples and any results indicated by the test equipment (16). Information on the tests run on a particular sample, the reagents used and the results produced by the tests, are maintained a database and may be formatted into a report.
Abstract:
A retortable plastic container (50) has a bottom wall having resting surface which surrounds a primary recessed portion (51). The primary recessed portion surrounds a secondary recessed portion (52). When the bottom wall of the container is viewed head-on the primary recessed portion (51) has an outline which is circular, while the secondary recessed portion (52) has an outline which is non-circular. The secondary recessed portion has major and minor axes which are mutually perpendicular and intersect one another on a longitudinal axis of the container. The distance (B) across the secondary recessed portion along the major axis divided by the distance (C) across the secondary recessed portion along the minor axis is greater than 1 but not greater than 3.
Abstract:
A laparoscopic gastrostomy instrumentation kit (10) includes means for securing a patient's stomach in apposition to the abdominal wall, means for creating a stoma, a gastrostomy tube (24) and a container for containing the components of the instrumentation kit (10). In preferred embodiments the instrumentation kit (10) includes T-Fasteners assemblies (18), syringes (15, 17 and 27) and a gastrostomy tube (24).
Abstract:
The present invention involves methods of detecting small mutations in target nucleic acid using the Ligase Chain Reaction (LCRTM). Detectable small mutations include single base deletions, insertions and changes, as well as multiple mutations (deletions, insertions and changes) where the size of the mutation is less than about 15 % of the average probe length. The methods include high concentrations of monovalent cations, especially Na+, K+ and NH4+; and/or relatively high initial mixing temperatures. The methods also include probe designs having deliberate mismatches with respect to target, the mismatches being near the 5' ends. Also claimed are several sets of probe sequences for detection of mutations associated with cystic fibrosis.